Design and synthesis of pentaseter analogs of didemnaketal A and B

ORGN 656

Xiaodong Fan, xfan@atherogenics.com, Medicinal Chemistry, AtheroGenics, Inc, 8995 Westside Parkway, Alpharetta, GA 30004 and Daniel H. Rich, dhrich@wisc.edu, School of Pharmacy & Department of Chemistry, University of Wisconsin-Madison, 7109 Rennebohm Hall, 777 Highland Ave, Madison, WI 53705.
The Didemnaketal A and B (1a,b) inhibit HIV protease with IC50s of 2 mM and 10 mM, respectively, and are early examples of HIV protease inhibitors that lack nitrogen. In the course of determining the key portion of these compounds that inhibits the protease, we have identified that the pentaester subunit inhibits the HIV-1 protease (see, Fan, X., et al, J. Am. Chem. Soc. 1998, 120, 8893). We then synthesized a series of pentaester analogs 2 and 3 of Didemnaketals. Synthetic efforts and structure activity studies of these compounds (2-3) will be presented.